Beijing Tiantan Biological Products Corp Ltd

Beijing Tiantan Biological’s 2025 Q3 results show solid revenue growth amid regulatory pauses and price pressure, while plasma collection surges and block‑trade activity confirm steady liquidity.

Beijing Tiantan Biological Products Corp Ltd’s stock surged as the company expands its production capabilities with a new state-of-the-art blood products production base in Lanzhou, China.

Beijing Tiantan Biological Products Corp Ltd, a Shanghai-listed biotech company, has seen significant market growth and is a top holding in several AI-managed funds, with a focus on hepatitis treatments and vaccines.